登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002828 证券简称：贝肯能源 公告编号：2025-075 贝肯能源控股集团股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 贝肯能源控股集团股份有限公司（以下简称"公司"）第六届董事会第五次会议于2025年7月30日上午 10:30在公司二楼会议室以现场结合通讯的方式召开，本次会议于2025年7月24日以传真、电子邮件和正 式文本等方式通知了全体董事。 本次会议应出席董事6名，实际出席董事6名。本次会议由董事长唐恺先生主持，公司高级管理人员列席 了本次会议，会议的通知、召集、召开和表决程序符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 会议以现场表决的方式形成了如下决议： 1、审议通过了《关于修订公司2025年度向特定对象发行A股股票方案的议案》 鉴于公司 2024年年度权益分派已实施完毕，并结合公司实际情况，经审议，董事会同意对公司2025年 度向特定对象发行A股股票方案的发行价格和募集资金总额进行修订。修订后的发 ...

0 刘利平 ◎记者 孔令仪 杨子晏 慢性代谢病牵一发而动全身，能否仅用一种药物，为患者提供综合性解决方案？ 与围绕单个靶点开发药物的方向不同，君圣泰医药另辟蹊径，尝试从天然产物中寻找答案，将传统中医 药文明与现代科技结合，开发出一款多靶点、可为患者带来综合获益的药物。 十余年耕耘，君圣泰医药创始人、董事长兼首席执行官刘利平带领团队，将黄连中的活性成分小檗碱 （亦称"黄连素"）和熊去氧胆酸，结合成一个全新的分子实体，成功研发了熊去氧胆小檗碱（研发代 码"HTD1801"）。 今年，君圣泰医药将向国家药监局递交HTD1801治疗2型糖尿病适应症的新药上市申请，正式迈向商业 化阶段。 在天然产物中寻找制药灵感 2011年之前，刘利平在国外已经主导过1项新药上市申请、10余项新药临床试验申请。凭借多年工作经 验，她意识到慢性代谢性疾病正在呈现共病化趋势，而单一靶点药物绝非最优解，应该开发多靶点、多 功效的药物，为患者的全身代谢网络提供综合调节。 彼时恰逢《国务院关于加快培育和发展战略性新兴产业的决定》发布，明确将生物产业列为重点培育和 发展的七大战略性新兴产业之一。 2011年，刘利平做出了一个改变人生轨迹的决定：回 ...

Core Insights - Zhongtian Technology has evolved from a local brick and tile factory to a leading high-end manufacturing enterprise, covering multiple sectors including communication, electric power, marine, and renewable energy, with operations in over 160 countries and regions [6][7][8] Innovation and Technology - The company successfully developed its first optical fiber preform in 2010, becoming the only domestic manufacturer with complete independent intellectual property rights at that time, breaking the monopoly held by a few foreign giants [9][10] - Zhongtian Technology has expanded its technological capabilities along the entire industry chain, focusing on key technologies such as multi-core and hollow-core fibers [9][10] - In the electric power sector, the company maintains a leading position in cables, wires, and fittings, continuously innovating in areas like insulators and transformers [10] - The company has made significant advancements in marine cable technology, including the development of a ±525kV DC submarine cable, marking a leap in China's DC cable technology [10] New Product Development - In 2024, Zhongtian Technology plans to introduce over 160 new products, with more than 30 recognized as internationally advanced [11] - The company has secured approximately 31.2 billion yuan in orders across various sectors, including marine and electric grid construction [11] Talent and Innovation Culture - Zhongtian Technology emphasizes talent cultivation and innovation, with over 2,700 R&D personnel, including a significant proportion of PhDs and Masters [14][15] - The company has established a talent fund of 50 million yuan to attract international and industry-leading talents [14] - The "Knowledge Property Bank" initiative encourages employee innovation by allowing them to convert suggestions into rewards [15] Global Expansion Strategy - The company aims to transition from "fine manufacturing" to "precise manufacturing" in 2024, responding to international competition and high standards from overseas clients [16][17] - Zhongtian Technology has established five overseas factories and numerous marketing centers since 2012, with nearly 20% of its revenue coming from international markets [17][18] - The company is focused on localizing operations in foreign markets, adapting to cultural differences, and building trust with local employees [18] Future Goals - The company aims to replicate its success internationally, with plans for further investment and trade expansion as part of its "Going Global 2.0" strategy [19]

Core Viewpoint - The article highlights the transformation of Xiandai Intelligent from a small workshop to a leading global smart equipment enterprise, emphasizing the leadership of Wang Yanqing and the company's focus on technological innovation and market expansion in solid-state batteries and energy storage solutions [7][9][10]. Company Development - Xiandai Intelligent has evolved from a modest capacitor equipment factory in Wuxi to a company with a market value exceeding 100 billion yuan, showcasing the entrepreneurial spirit and technical expertise of its founder Wang Yanqing [7][8]. - The company has successfully delivered multiple sets of core equipment for solid-state batteries to a leading global battery manufacturer, marking a significant milestone in the commercialization of solid-state battery technology [9][10]. Technological Innovation - Wang Yanqing emphasizes the importance of technological innovation, stating that the company has developed a complete set of core technologies for solid-state batteries, achieving 100% independent intellectual property rights [9][10]. - The company has also established a comprehensive value chain solution for energy storage, with cumulative orders exceeding 300 GWh [10][11]. Market Strategy - Xiandai Intelligent is actively expanding its overseas business, aiming for international markets to account for 50% of its operations, with a focus on establishing localized service networks in Europe and North America [13][14]. - The company is capturing growth opportunities in emerging markets such as Southeast Asia, the Middle East, and Latin America, with branches already set up in Malaysia and Turkey [13][14]. Industry Perspective - The article discusses the cyclical nature of the lithium battery industry, with Wang Yanqing suggesting that current market adjustments are necessary for the elimination of outdated capacities and the emergence of high-quality production demands [12][14]. - The company is positioned to navigate industry cycles through technological advancements and a robust global strategy, focusing on value creation and avoiding ineffective competition [14].

Group 1 - The Chinese innovative drug industry is transitioning from "follow-up innovation" to "global leadership," with a record number of innovative drugs approved in the first half of the year [1][2] - In the first half of 2023, 43 innovative drugs were approved in China, representing a 59% year-on-year increase, compared to only 48 approvals for the entire year of 2024 [2][3] - China's innovative drug R&D pipeline accounts for about one-fourth of the global total, with approximately 3,000 clinical trials conducted annually, placing China at the forefront of global innovative drug development [2][3] Group 2 - Companies like Fosun Pharma and Hengrui Medicine have successfully launched multiple innovative drugs, with Hengrui having 23 first-class innovative drugs and 4 second-class innovative drugs approved domestically [3][4] - The commercialization of innovative drugs is leading to a recovery in performance for domestic pharmaceutical companies, with companies like Luoxin Pharma and MicuRx reporting significant profit increases [3][4] - The trend of Chinese pharmaceutical companies expanding internationally is accelerating, with a shift from license-in to explosive growth in license-out transactions, contributing nearly 50% of the total transaction value globally [4][5] Group 3 - Notable license-out deals include a partnership between 3SBio and Pfizer, with an upfront payment of $1.25 billion and a potential total deal value of $6.05 billion, setting a record for Chinese innovative drugs [5][6] - The rapid growth of license-out transactions is providing substantial cash flow for domestic innovative drug companies, supporting their core pipelines overseas and creating more collaboration opportunities with multinational pharmaceutical companies [6]

Core Viewpoint - The trend of mid-term cash dividends among listed companies in the Shanghai Stock Exchange is increasing, with many companies announcing their mid-term dividend plans for 2025, reflecting a strong commitment to shareholder returns [2][6]. Group 1: Mid-term Dividend Announcements - Weisheng Information plans to distribute a cash dividend of 122 million yuan, accounting for 40% of its net profit for the first half of 2025, marking its first mid-term dividend [2][3]. - WuXi AppTec has also announced a mid-term cash dividend of 3.5 yuan per 10 shares, with a total cash dividend of 1.03 billion yuan, following a significant increase in revenue and net profit [3][4]. - Dongpeng Beverage has proposed a cash dividend of 2.5 yuan per share, amounting to 1.3 billion yuan, continuing its trend of substantial mid-term dividends [4][7]. Group 2: Overall Dividend Trends - In 2023, 1,501 listed companies in the Shanghai Stock Exchange distributed a total of 1.38 trillion yuan in cash dividends, indicating a robust dividend culture [2]. - The number of companies implementing mid-term dividends has surged, with 504 companies distributing over 580 billion yuan in 2024, representing a significant increase compared to previous years [6]. - The Shanghai Stock Exchange is encouraging companies to enhance their dividend policies, aiming to improve shareholder returns through various financial management tools [6][7]. Group 3: Notable Companies and Their Dividend Policies - Companies like East China Sea Group and Agricultural Bank of China have initiated mid-term dividends for the first time, while others like China Construction Bank have resumed mid-term dividends after several years [6]. - Companies such as Linglong Tire and Tian Shili have adopted a multi-tiered dividend strategy, distributing dividends multiple times within a year to reinforce investor confidence [6][7]. - The cumulative cash dividends of WuXi AppTec since its listing in 2018 have reached approximately 13 billion yuan, with a consistent payout ratio of around 30% of its net profit [4][5].

◎记者 李少鹏 受益于游戏行业供需两旺及出海业务的亮眼表现，上半年游戏行业用户活跃度和收入规模等数据明显提 升，多数游戏公司有望交出一份亮眼的半年度成绩单。 据上海证券报记者统计，已披露上半年业绩预告的游戏公司整体表现不错，ST华通、浙数文化、游族 网络盈利大幅预增，完美世界、冰川网络、文投控股等预计成功扭亏，且盈利能力有大幅改善。 "从需求和供给及政策面看，今年游戏行业表现还是不错。游戏版号发放常态化推动更多新游上市，促 进了游戏公司的业绩释放。"在A股某游戏公司人士看来，随着更多符合市场需求的精品游戏陆续上 市，行业景气度预计保持向好势头。 游戏公司"中考"业绩预喜 亮眼的业绩预告靠什么支撑？多家游戏公司给出的答案基本一致——在营游戏和新品表现亮眼及海外市 场持续增长，游戏业务板块整体的活跃用户和流水增幅较大。 以业绩预告净利润下限大幅领先同行的ST华通为例，公司预计上半年实现净利润24亿元至30亿元，同 比增长107.20%至159.00%。对于业绩大幅预增，公司表示，主要系子公司点点互动表现优异，其国内 及海外收入均持续保持稳健的增长态势，使得公司上半年收入及利润均实现同比大幅增长。同时，公司 预计上 ...

Group 1 - The company issued 20 billion RMB of convertible bonds named "欧22转债" on August 5, 2022, with a maturity of six years and a tiered interest rate starting from 0.30% in the first year to 2.00% in the sixth year [2][3] - The initial conversion price was set at 125.46 RMB per share, which has been adjusted to 118.48 RMB per share due to the company's profit distribution and stock option exercises [3][4] - The conversion price can be adjusted downwards if the stock price falls below 80% of the current conversion price for at least 15 out of 30 consecutive trading days, requiring a two-thirds majority approval from shareholders [4][5] Group 2 - The company decided not to adjust the conversion price on June 16, 2025, and if the conditions for adjustment are triggered again within one month, it will also not adjust the price [5][6] - From July 17, 2025, if the stock price remains below 94.78 RMB per share for 5 out of the next 20 trading days, it will trigger the conditions for a downward adjustment of the conversion price [6]

二、本次质押股份不存在用作重大资产重组业绩补偿等事项的担保或其他保障用途。 证券代码：605016 证券简称：百龙创园 公告编号：2025-044 山东百龙创园生物科技股份有限公司 关于控股股东一致行动人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 ●山东百龙创园生物科技股份有限公司（以下简称"公司"）控股股东一致行动人窦光朋先生持有公司股 份10,086,258股，占公司总股本的比例为2.40%。本次质押后，窦光朋先生股份累计质押数量为 7,000,000股，占其所持有公司股份总额的比例为69.40%，占公司总股本的比例为1.67%。 一、本次股份质押的具体情况 公司于2025年7月30日获悉控股股东一致行动人窦光朋先生所持公司的部分股份被质押，具体事项如 下： ■ 三、股东累计质押股份情况 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下： ■ 特此公告。 山东百龙创园生物科技股份有限公司董事会 2025年7月31日 ...

Group 1 - The company has approved a share repurchase plan using self-owned and self-raised funds through centralized bidding, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [4][5] - The repurchase period is set to not exceed 12 months from the date of board approval [4] - The company has obtained a loan commitment letter from a financial institution, allowing for a loan of up to RMB 180 million, which can cover up to 90% of the total repurchase funds [5][7] Group 2 - The loan is designated specifically for the purpose of repurchasing company shares and has a maximum term of 3 years [5] - The commitment letter is valid until July 15, 2026, and the actual repurchase amount and quantity will depend on market conditions and the availability of funds [7]